Cardiac Guidance vs ClearRead CT

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Cardiac Guidance

by Caption Health

ClearRead CT

by Riverain Technologies

AI Verdict

Tool A, Cardiac Guidance, focuses on empowering healthcare professionals to acquire and interpret diagnostic-quality cardiac ultrasound images at the point of care. In contrast, Tool B, ClearRead CT, enhances the detection and analysis of pulmonary nodules and coronary artery calcification in CT scans. While both are FDA-cleared AI tools within the broader cardiothoracic imaging space, they utilize different imaging modalities (ultrasound vs. CT) and address distinct clinical workflows, making them complementary rather than directly competitive.

Choose Cardiac Guidance if…

Choose Cardiac Guidance if your organization aims to expand access to diagnostic-quality cardiac ultrasound by empowering non-expert users at the point of care. This tool is ideal for settings like emergency departments or remote clinics where rapid, accurate cardiac assessments are needed without immediate access to specialized sonographers, enabling efficient bedside evaluations.

View Cardiac Guidance →

Choose ClearRead CT if…

Choose ClearRead CT if your radiology department seeks to enhance the accuracy and efficiency of cardiothoracic CT scan interpretation, especially for pulmonary nodule detection and coronary artery calcification scoring. This AI suite is best suited for improving lung cancer screening programs, streamlining nodule tracking, and leveraging existing non-contrast CTs for cardiovascular risk assessment, ultimately reducing reading times and improving diagnostic confidence.

View ClearRead CT →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Cardiac Guidance	ClearRead CT
Pricing	Unknown	Contact for pricing
Deployment	Caption Guidance is deployed in acute point-of-care settings, including emergency and anesthesiology departments and critical care units. It is also used in doctors' offices and can be used for at-home care.	On-premise (stand-alone server, virtual machine) and Cloud
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cardiac Guidance

Cardiac Guidance (Tool A) is explicitly designed to enable non-expert ultrasound users to acquire diagnostic-quality images through real-time AI guidance and turn-by-turn instructions. This focus on democratizing a complex skill makes it highly usable for a broader range of healthcare professionals. ClearRead CT (Tool B), while improving efficiency for radiologists, does not offer the same level of guidance for novice users.

Clinical Value

ClearRead CT

ClearRead CT (Tool B) offers a quantifiable improvement in diagnostic accuracy, with a reported 29% reduction in missed actionable pulmonary nodules, and also provides automated nodule tracking and coronary artery calcification scoring. While Cardiac Guidance (Tool A) democratizes access to cardiac assessments, Tool B provides a direct and measurable enhancement to the detection of critical findings in existing CT workflows, leading to more confident and accurate diagnoses.

Pricing & Value

Tie

Both Cardiac Guidance (Tool A) and ClearRead CT (Tool B) state that pricing information is available upon contacting the vendor. Without specific pricing details or publicly available cost-benefit analyses for either product, it is impossible to determine which offers better value. Therefore, this dimension is a tie.

Enterprise Readiness

ClearRead CT

ClearRead CT (Tool B) explicitly highlights 'Seamless PACS Integration / Vendor-neutral processing' and offers flexible deployment options including on-premise (stand-alone server, virtual machine) and cloud. This indicates a robust design for integration into diverse enterprise IT infrastructures. Cardiac Guidance (Tool A) is deployed as a software accessory integrated with specific ultrasound systems, which may offer less broad enterprise flexibility.

Innovation

Cardiac Guidance

Cardiac Guidance (Tool A) demonstrates significant innovation by providing real-time AI guidance and turn-by-turn instructions to enable non-expert users to acquire diagnostic-quality cardiac ultrasound images. This approach fundamentally democratizes access to a complex diagnostic skill. While ClearRead CT (Tool B) features patented vessel suppression and automated nodule tracking, Tool A's innovation has a broader impact on healthcare delivery by expanding the pool of capable users for critical cardiac assessments.

Support & Docs

Tie

Neither the provided structured facts nor readily available public information for Caption Health's Cardiac Guidance (Tool A) or Riverain Technologies' ClearRead CT (Tool B) offer specific details regarding their support channels, service level agreements, or publicly accessible documentation. Without this information, it is not possible to differentiate between the two tools on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Cardiac Guidance	ClearRead CT
Primary Function	AI tool for acquiring and interpreting diagnostic-quality cardiac ultrasound images at the point of care.	AI suite for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans.
Company	Caption Health	RIVERAIN TECHNOLOGIES
Target Modality	Cardiac ultrasound images	CT scans
Key AI Capability 1	Real-time AI guidance for cardiac ultrasound image acquisition	Pulmonary Nodule Detection (solid, part-solid, ground glass)
Key AI Capability 2	Automated left ventricular ejection fraction (EF) calculation	Patented Vessel Suppression (Clear Visual Intelligence)
Key AI Capability 3	Support for 10 standard echocardiographic views (e.g., PLAX, AP4, AP2)	Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs)

Videos

Demos, reviews, and walkthroughs featuring Cardiac Guidance and ClearRead CT.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What imaging modalities do Cardiac Guidance and ClearRead CT utilize?

Cardiac Guidance is an AI tool designed for acquiring and interpreting diagnostic-quality cardiac ultrasound images. ClearRead CT is an AI suite that enhances the analysis of CT scans for cardiothoracic health.

What are the primary clinical applications for each tool?

Cardiac Guidance empowers healthcare professionals to acquire and interpret cardiac ultrasound images at the point of care, including automated left ventricular ejection fraction (EF) calculation. ClearRead CT focuses on enhancing pulmonary nodule detection and performing coronary artery calcification (CAC) analysis in CT scans.

Which tool is designed to assist users with real-time image acquisition guidance?

Cardiac Guidance provides real-time AI guidance for cardiac ultrasound image acquisition, offering turn-by-turn on-screen probe movement instructions and automated quality assessment. ClearRead CT focuses on post-acquisition analysis of CT images.

What specific diagnostic measurements or analyses do these tools provide?

Cardiac Guidance offers automated left ventricular ejection fraction (EF) calculation and supports 10 standard echocardiographic views. ClearRead CT provides pulmonary nodule characterization and measurement (volume, diameter, location, type, depth), automated nodule tracking, and coronary artery calcification (CAC) scoring.

Do these tools offer features to improve workflow efficiency or diagnostic accuracy?

Cardiac Guidance aims to democratize access to cardiac assessments by enabling non-expert ultrasound users to acquire diagnostic-quality images. ClearRead CT is designed to reduce reading times by up to 36% and improve detection accuracy with a 29% reduction in missed actionable nodules.